In breast cancer, MM-121’s therapeutic potential is being tested in patients with ER and/or PR positive and erbB2 negative breast cancers in combination with the aromatase inhibitor exemestane, and in patients with triple negative or erbB2 negative breast cancers in combination with paclitaxel. This evidence concerns the gene CYP19A1 and breast cancer.